3G6.F GNI Group Ltd

Healthcare Biotechnology Frankfurt Exchange
11.70 EUR
Close of Nov 12, 2026
11.20 20.00
Market cap
EUR 770M
P/E
-
P/B
3.46x
ROE
-9.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 3G6.F undervalued?

Graham number

The Graham number of GNI Group Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GNI Group Ltd fundamental analysis

No fundamental analysis for GNI Group Ltd yet.

GNI Group Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GNI Group Ltd

GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics pro…

Full company profile